Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
LUND, Sweden, April 28, 2016 --
Laquinimod
- The clinical Phase 3 study CONCERTO, 0.6 mg/day, in relapsing remitting multiple sclerosis (RRMS), with the aim to obtain market approval in the US and Europe, is proceeding according to plan. Study results are expected in the first half of 2017
- The clinical Phase 2 study ARPEGGIO for the treatment of primary progressive multiple sclerosis (PPMS) is proceeding according to plan
- The clinical Phase 2 study LEGATO-HD for the treatment of Huntington's disease is proceeding according to plan
- Extension studies with 0.6 mg laquinimod in patients from the Phase 3 studies ALLEGRO and BRAVO are proceeding according to plan
- As earlier communicated the highest dose groups in the clinical studies CONCERTO, ARPEGGIO and LEGATO-HD have been discontinued due to cardiovascular events
Tasquinimod
- In March 2016, it was announced that the company plans to develop tasquinimod to treat multiple myeloma and intends to seek a collaboration partner for the project
- An expanded analysis of the secondary endpoints in the 10TASQ10 study was presented at the ASCO GU Symposium in January 2016. The results showed that tasquinimod had positive effects on both radiographic and PSA-based endpoints. However, as previously communicated, overall survival (OS) was not extended, prompting the discontinuation of all further development within prostate cancer
ANYARA, Paquinimod (57-57) and SILC (ISI)
- Out-licensing activities are continuing
Financial summary
| MSEK | Jan. - Mar. | Full Year | |||
| 2016 | 2015 | 2015 | |||
| Net sales | 3.9 | 2.9 | 16.3 | ||
| Operating loss | -16.1 | -57.4 | -177.9 | ||
| Loss for the period | -16.8 | -58.0 | -193.5 | ||
| Loss per share, before and after dilution (SEK) | -0.19 | -0.64 | -2.15 | ||
| Cash and cash equivalents (at the end of the period) | 76.5 | 270.5 | 103.6 | ||
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 05
The report is also available at www.activebiotech.com.
Active Biotech AB (publ) Interim report January - March 2016 http://hugin.info/1002/R/2007548/742184.pdf
HUG#2007548
